On­corus plots ear­ly-stage plant in Boston area as it walks I-O can­di­date through the clin­ic

Buoyed by what it called a suc­cess­ful 2020, Mass­a­chu­setts-based On­corus has snared a lease in the Boston area to lock down a man­u­fac­tur­ing site for its clin­i­cal-stage on­col­o­gy port­fo­lio.

On­corus, a five-year-old com­pa­ny, an­nounced Mon­day that it signed a 15-year lease to build an 88,000-square-foot GMP vi­ral im­munother­a­py clin­i­cal man­u­fac­tur­ing fa­cil­i­ty in An­dover, MA.

The com­pa­ny said in a press re­lease that it an­tic­i­pates the first phase of the fa­cil­i­ty will be fin­ished by the end of 2021 and will pri­or­i­tize process de­vel­op­ment and qual­i­ty con­trol. Once ful­ly op­er­a­tional — pro­ject­ed in 2023 — On­corus plans to have GMP mul­ti-prod­uct man­u­fac­tur­ing ca­pa­bil­i­ties avail­able to pro­duce clin­i­cal-grade vi­ral im­munother­a­pies for in­ves­ti­ga­tion­al new drug and clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER